BioSpace News Archive

BD (Becton, Dickinson and Company) (NYSE: BDX) announced today that it will report its fiscal 2022 fourth quarter and full year financial results on Thursday, November 10, 2022.

Universal Health Services, Inc. (NYSE: UHS) announced today that it will report results for its third quarter ended September 30, 2022, after the market closes on Tuesday, October 25, 2022.

Enliven Therapeutics, Inc. (Enliven), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, and Imara Inc. (Nasdaq: IMRA) (Imara) today announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction.

Labcorp (NYSE: LH), a leading global life sciences company, today announced that Kirsten Kliphouse, president of Americas, Google Cloud, has joined its Board of Directors as an independent member.

Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” “our,” “us,” or “we”), a clinical-stage biopharmaceutical company, announced that the U.S. Food and Drug Administration (“FDA”) has informed the Company that it does not plan to hold an advisory committee meeting in connection with its review of the Company’s New Drug Application (“NDA”) for omaveloxolone for the treatment of patients with Friedreich’s ataxia.

Biomerica, Inc., a global provider of advanced medical products, reported net sales for the three months ended August 31, 2022 of $1.67 million, versus net sales of $1.26 million for the same period in the previous year, a 30% increase.

AptarGroup, Inc., a global leader in drug delivery, consumer product dispensing and active material science solutions and services, declared a quarterly cash dividend of $0.38 per share.

ulrich medical USA, Inc., a privately held medical device company focused on developing and commercializing musculoskeletal implant technologies in the United States, today announced the FDA has given 510(k) clearance of its Flux-C 3D printed porous titanium cervical interbody device.

Allergy Partners, the nation’s largest single specialty allergy practice group leading the development and delivery of high-quality health care for patients with asthma and allergic disease, today announced a strategic collaboration with Aimmune Therapeutics, Inc.

Transcenta Holding Limited (“Transcenta”) (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that it will present two scientific posters at the 37th Society for Immunotherapy of Cancer’s (SITC) Annual Meeting in Boston, MA.